ClinicalTrials.gg
RecruitingNCT07363876Updated Sep 30, 2026

The Efficacy of Ultrasonication in Combination With Corticosteroid Intraarticular Injection for Arthritis

An interventional study of Therapeutic Ultrasound and Intra-articular corticosteroid injection in Arthritis, Ultrasonication and Intra-articular Injections, sponsored by Taichung Veterans General Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Taichung Veterans General Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.
Updated Sep 30, 2026Now RecruitingFirst site in Taiwan+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Arthritis with a site in Taiwan — 3 open to participants now, 4 under way, 1 of them phase 3. Arthritis · Taiwan.

Planned enrollment
13th of 15
100 · median 529
Started
2026
the only one that year
No phase
3 of 16
3 open now
Registered
16th of 16
by date
Lead sponsor
1 of 16
Taichung Veterans General Hospital

Among the 16 studies in Arthritis with a site in Taiwan, this one is the 13th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2026, is one of 3 with no phase, and was the 16th registered.

Arthritis

843 studies on the registry are indexed under Arthritis; 118 are open to participants now.

Browse Arthritis studies →

Open to participants now

3 of the 16 studies in Arthritis with a site in Taiwan are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 78 Arthritis studies recruiting now, 41 (53%) set no upper age limit and 20 (26%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Arthritis with a site in Taiwan, or all of them as a file.
02

Study summary

This study investigates whether ultrasound therapy applied prior to intra-articular corticosteroid injection can enhance the treatment efficacy for patients with joint arthritis and assess its safety. Adult patients diagnosed with arthritis in the limbs who are indicated for corticosteroid injection are eligible, while patients with joint replacement, hip joint involvement, gout, infectious arthritis, or local cellulitis are excluded.

Ultrasound therapy is a valuable physical therapy tool for musculoskeletal diseases, producing therapeutic effects through thermal and non-thermal mechanisms. It can improve tissue extensibility, reduce joint stiffness, increase local blood flow, enhance metabolism during tissue repair, and facilitate drug absorption. This study evaluates whether applying ultrasound before intra-articular corticosteroid injection improves therapeutic outcomes in patients with arthritis, and assesses the safety of this combined intervention. Patients aged 18 or older, diagnosed with limb arthritis, and indicated for corticosteroid injection are eligible. Exclusion criteria include joint replacement, hip joint involvement, gout, infectious arthritis, or local cellulitis at the treatment site.

03

Conditions studied

  • Arthritis
  • Ultrasonication
  • Intra-articular Injections
  • Rheumatology

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older.
  • Diagnosed with arthritis in the limbs.
  • Inadequate response to or for oral anti-inflammatory medications.
  • Assessed by a physician as requiring intra-articular injection.

Exclusion criteria

Exclusion Criteria:

  • History of joint replacement (prosthetic joint) in the affected area.
  • Hip joint involvement.
  • Diagnosis of gout.
  • Infectious arthritis.
  • Presence of cellulitis at the treatment site.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    ultrasonication in combination with corticosteroid intraarticular injection

    Device: Therapeutic Ultrasound · Procedure: Intra-articular corticosteroid injection

  • Active comparator
    corticosteroid intraarticular injection

    Procedure: Intra-articular corticosteroid injection

Interventions

  • DeviceTherapeutic Ultrasound

    Therapeutic Ultrasound (TUS) is a non-invasive treatment widely used in physical medicine and rehabilitation for musculoskeletal conditions. Since its introduction in the mid-20th century, TUS has gained popularity in clinical practice due to its ability to penetrate tissues, target treatment areas precisely, and exhibit minimal side effects. This study aims to investigate the mechanisms of action, clinical efficacy, and safety of therapeutic ultrasound in musculoskeletal therapy.

  • ProcedureIntra-articular corticosteroid injection

    Injection of triamcinolone (3-50 mg depending on joint size) into the affected joint. Administered once per participant.

06

What researchers measure

Primary outcomes

  1. Reduction in Synovial Swelling Area Assessed by Joint Ultrasound

    Synovial swelling area (pixels) assessed by joint ultrasound. A treatment response is defined as a ≥50% reduction in synovial swelling area from baseline.

    Time frame: From enrollment to the end of treatment at 2 weeks

  2. Change in Power Doppler (PD) Score of the Target Joint

    Power Doppler (PD) score (range 0-3) of the target joint assessed by joint ultrasound. A treatment response is defined as a PD score of 0 at 2 weeks post-treatment.

    Time frame: From enrollment to the end of treatment at 2 weeks

  3. Change in Pain Visual Analogue Scale (VAS)

    Pain intensity assessed using a visual analogue scale (VAS 0-10). A treatment response is defined as a ≥50% reduction in VAS score from baseline or a VAS score ≤1 at 2 weeks post-treatment.

    Time frame: From enrollment to the end of treatment at 2 weeks

Secondary outcomes

  1. Absence of Synovitis Recurrence Based on Power Doppler (PD) Score

    Absence of synovitis recurrence assessed by Power Doppler (PD) ultrasound. Recurrence is defined as any increase in PD score compared with the 2-week post-treatment assessment.

    Time frame: From enrollment to 3 months post-treatment

  2. Absence of Synovial Swelling Recurrence on Gray-Scale Ultrasound

    Absence of synovial swelling recurrence assessed by gray-scale ultrasound. Recurrence is defined as an increase in synovial swelling area of ≥20% compared with the 2-week post-treatment assessment.

    Time frame: From enrollment to 3 months post-treatment

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Nov 2026, 9 months after the start.

Of 133 non-industry interventional studies with no phase under Arthritis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 9 months is below that.

Counting every sponsor, half of 166 studies reached it within 31 months; a quarter within 13 and three quarters within 65.

Start moved once since we started tracking on Sep 25, 2026: Dec 2025 → Feb 2026, on Sep 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2026
First posted
Jan 23, 2026
StartActual
Feb 26, 2026was Dec 2025
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 30, 2026
Sites
1 site added — first site in Taiwan
Show site
  • Taichung Veterans General Hospital · Taichung, Taiwan
Sep 30, 2026
Start date
Dec 29, 2025→Feb 26, 2026 (actual)
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Taiwan
    Show site
    • Taichung Veterans General Hospital · Taichung, Taiwan
    Start date Dec 29, 2025→Feb 26, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07363876
Responsible party
Kuo-Lung Lai (Principal Investigator, Taichung Veterans General Hospital) — Principal investigator
First posted
Jan 23, 2026
Start date
Feb 26, 2026
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 30, 2026

Study contacts

Kuo-Lung Lai, MD
Contact
kllaichiayi@yahoo.com.tw
+886-4-2359-2525
Kuo-Lung Lai, MD
principal investigator · Taichung Veterans General Hospital (TaichungVGH)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion